


Iridium-Catalyzed Direct Synthesis of Tryptamine Derivatives from Indoles: Exploiting N-Protected β -Amino Alcohols as Alkylating Agents

Silvia Bartolucci, Michele Mari, Annalida Bedini, Giovanni Piersanti,* and Gilberto Spadoni

Department of Biomolecular Sciences, University of Urbino “Carlo Bo”, Piazza del Rinascimento 6, 61029 Urbino (PU), Italy

S Supporting Information

ABSTRACT: The selective C3-alkylation of indoles with N-protected ethanolamines involving the “borrowing hydrogen” strategy is described. This method provides convenient and sustainable access to several tryptamine derivatives.



INTRODUCTION

The tryptamine moiety is found in a number of drugs and is a common motif in countless naturally occurring compounds that use L-tryptophan as a biosynthetic precursor.¹ The direct and selective construction of tryptamine derivatives from simple and sustainable starting materials using a catalytic system provides convenient access to a range of structurally diverse natural products, pharmaceutical compounds, potential building blocks for indole alkaloid chemistry, and other polynitrogenated compounds.² Although methods accessing these bioactive molecules have been reported, there are few one-step transformations that provide access to tryptamines. Classical methods involve the C-3 Friedel–Crafts alkylation of indoles³ with either nitroalkenes⁴ or aziridines⁵ as the electrophilic partner, promoted by Lewis acids and/or organocatalysts. However, due to the toxicity and instability of these strongly electrophilic reactants⁶ as well as selectivity issues during the required extra reduction step of the nitro group and/or aziridine ring opening, a more sustainable and efficient method is highly desired.⁷ In the search for new suitable two-carbon nitrogen-containing electrophiles, we recently described the efficient use of N-protected aminoethyl acetals for the reductive alkylation of indoles,⁸ giving access to tryptamine derivatives in a single step. During the course of this study, we found that acyl protection of the amine side chain was necessary to achieve acceptable levels of reactivity. Although this approach employs safe and inexpensive reagents, proceeds under mild conditions, and tolerates several functional groups, the shortcomings associated with completely unsubstituted indoles as well as a large excess of the reducing agent and TFA prompted us to investigate a novel catalytic and less wasteful method encompassing a wider range of indoles without the need for an external reductant.

The so-called “borrowing hydrogen” methodology (also named as “hydrogen autotransfer”), in which dehydrogenation of poorly reactive alcohols is followed by in situ consumption of the generated hydrogen equivalents, has gained acceptance as an efficient synthetic strategy in organic synthesis. Seminal work by Grigg and Watanabe⁹ as well as extensive studies by many other groups¹⁰ have shown that in the presence of


transition-metal catalysts (usually ruthenium or iridium complexes), poorly reactive alcohols are useful electrophilic partners for N-alkylation and C–C bond formation in which amines and methylene carbon acids are typically used as nucleophiles.¹¹ The use of a neutral electron-rich aromatic system with alcohols in the direct transition-metal-catalyzed alkylation has also been reported. However, to the best of our knowledge, there are no examples using the “borrowing hydrogen” strategy for the synthesis of tryptamine derivatives, despite the synthetic advantages of such an approach.¹² Herein, we report the development of an effective protocol for the direct Ir-catalyzed alkylation of indoles with N-protected ethanolamines to afford tryptamine derivatives. This strategy could open attractive possibilities for the total synthesis of tryptamine-based alkaloids.

RESULTS AND DISCUSSION

Preliminary studies were carried out at 150 °C in a sealed tube, using commercially available N-acetyethanolamine (**2a**) and unsubstituted indole (**1a**) in the presence of substoichiometric amounts of KOH (20%). A variety of transition-metal catalysts well-known to be highly active in hydrogen autotransfer reactions, including Pd/C, RuCl₂(PPh₃)₃, [Ir(cod)Cl]₂, [Ir-(coe)₂Cl]₂, [Ir(OMe)(cod)]₂, and RuHCl(CO)(PPh₃)₃, were screened. We found that the iridium dimer [Cp*IrCl₂]₂¹³ was the most efficient catalyst. After 48 h, we observed complete consumption of the indole and selective formation of the desired N-acetyltryptamine (35% yield; Table 1, entry 9), without traces of the N₁-alkylated product. The discrepancy between conversion and yield (Table 1) is mainly explained by the formation of two side products: the bis(3-indolyl)methane species **4** and tryptophol (**5**). The bis(indole) **4**, arising from addition of indole to the transient azafulvene,¹⁴ did not undergo conversion to **3a** under the reaction conditions, but some degradation of **4** did take place, suggesting that **4** is not a plausible intermediate of the reaction. In contrast, the

Received: January 28, 2015

Published: February 20, 2015

Table 1. Optimization of Reaction Conditions^a

entry	catalyst/ligand	base	conversn (%) ^b	yield (%) ^c		
				3a	4	5
1	Pd/C	KOH ^f	0			
2	RuCl ₂ (PPh ₃) ₃	KOH ^f	0			
3	[Cp*RhCl ₂] ₂	KOH ^f	41	11	12	6
4	[Ir(coe) ₂ Cl] ₂	KOH ^f	55	30	10	5
5	[Ir(OMe)(cod)] ₂	KOH ^f	47	18	12	5
6	[Cp*Ir(bpy)Cl]	KOH ^f	52	27	9	7
7	[Cp*Ir(Pro)Cl]	KOH ^f	54	33	8	5
8	[IrCl(cod)] ₂	KOH ^f	42	12	12	6
9	[Cp*IrCl ₂] ₂	KOH ^f	66	35	12	7
10	[Cp*IrCl ₂] ₂	KOH	68	39	10	9
11	[Cp*IrCl ₂] ₂	<i>t</i> BuOK	62	30	12	8
12	[Cp*IrCl ₂] ₂	<i>t</i> BuONa	66	30	14	8
13	[Cp*IrCl ₂] ₂	NaHCO ₃	63	14	20	9
14	[Cp*IrCl ₂] ₂	KOAc	64	12	21	10
15	[Cp*IrCl ₂] ₂	K ₃ PO ₄	62	16	19	8
16	[Cp*IrCl ₂] ₂	Cs ₂ CO ₃	>95	60	9	6
17	[Cp*IrCl ₂] ₂	Cs ₂ CO ₃ ^f	52	10	17	8
18 ^d	[Cp*IrCl ₂] ₂	Cs ₂ CO ₃	35	14	8	5
19 ^e	[Cp*IrCl ₂] ₂	Cs ₂ CO ₃	>95	56	10	9
20	[Cp*IrCl ₂] ₂		23	5	9	
21		Cs ₂ CO ₃	0			


^aConditions: indole (1 equiv), *N*-acetyethanolamine (3 equiv), catalyst (2.5 mol %), and base (1.1 equiv) at 150 °C for 48 h. ^bDetermined by ¹H NMR analysis of the crude reaction mixture. ^cIsolated yield. ^d1 equiv of *N*-acetyethanolamine was used. ^e10 equiv of *N*-acetyethanolamine was used. ^fBase (0.2 equiv).

formation of the byproduct **5** could be explained by the formation of the intermediate amido aldehyde, which is in equilibrium/tautomerization with the reactive *N*-acetylminium species that undergoes amidoalkylation with the incoming indole, prior to return of hydrogen. This sequence accounts for the different regioselectivities in the alkylation process, without a less direct C–N oxidation step.¹⁵ Although to obtain pure **3a** flash chromatography on silica gel was necessary, the removal of side products was simple due to their small amount and high lipophilicity in comparison to tryptamines.

Next, we investigated the influence of the base on the model reaction. Increasing the quantity of base to a stoichiometric amount slightly improved the yield of the reaction (Table 1, entry 10). Most importantly, we discovered that when powdered Cs₂CO₃ was used as the base, the desired *N*-acetyltryptamine was obtained in a synthetically useful yield (Table 1, entry 16). Lower conversions were generally observed when stronger bases such as *t*-BuOK and *t*-BuONa were employed (Table 1, entries 11 and 12), presumably due to partial hydrolysis of the ethanolamide used as the electrophile. A very low amount of the desired *N*-acetyltryptamine was also obtained by using solid NaHCO₃ or K₃PO₄ as the base (Table 1, entries 13 and 15), highlighting the importance of Cs₂CO₃ in this reaction. As expected, the reaction without the use of catalyst failed to provide the desired product, and the starting material was recovered (Table 1, entry 21). On comparison of the amounts of electrophile used, the best results were obtained

by applying 3 equiv of *N*-acetyethanolamine (Table 1, entries 16, 18, and 19). Interestingly, no overalkylation products were ever observed.


With the optimal reaction conditions established, we sought to probe the scope of the amine protecting groups that are amenable to this procedure. We investigated the use of alternative protecting groups that not only would allow efficient alkylation but also would be removed easily under relatively mild conditions. We tried to replace *N*-Ac with a traditional, easily removable amino protecting group such *N*-COCF₃, *N*-Cbz, or *N*-Ts. Unfortunately, *N*-COCF₃ and *N*-Cbz were very unstable and decomposed quickly under the basic reaction conditions. Interestingly, using *N*-Cbz-ethanolamine, we obtained only 3-benzylindole, which probably formed by the borrowing hydrogen reaction of indole with benzyl alcohol generated by an intramolecular cyclization to the corresponding oxazolidinone. Accordingly, *N*-benzylethanolamine (**2c**) selectively furnished the desired *N*-benzyltryptamine, though in a yield lower than that for *N*-acetyethanolamine (**2a**) (Scheme 1). In sharp contrast, the reaction of *N*-Ts-ethanolamine failed to provide the expected product, and the starting material was recovered almost quantitatively. We believe that a stable sulfonamido-iridium complex is formed, blocking the metal from participating productively in the catalytic cycle. Finally, when the phthalimido group was used as a protecting group, a complex mixture of products was obtained (probably because it was partially reduced), precluding its use in our protocol. When

Scheme 1. Alkylation of Indole with *N*-Alkylethanolamines

simple unprotected 2-aminoethanol was used, no reaction occurred, whereas using *N,N*-dimethylethanolamine resulted in a gratifying 42% yield (Scheme 1).¹⁶

Next, we examined a spectrum of substituted indoles to explore the generality of this novel reaction. A range of differently substituted indoles (1a–l), with electron-donating or -withdrawing groups in all possible positions, gave moderate to good yields (36–78%) of the corresponding tryptamine derivative, although different reactivities were observed. For example, the electron-rich 5-methoxyindole was converted in a very good yield and selectivity to give melatonin (3b) as the desired product (Table 2), whereas lower than normal yields

Table 2. Alkylation of Substituted Indoles with *N*-Acetyethanolamine using $[\text{Cp}^*\text{IrCl}_2]_2$ and Cs_2CO_3 ^a




^aReactions were carried out in a sealed vial at 150 °C for 48 h with indole (0.25 mmol), *N*-acetyethanolamine (0.75 mmol), $[\text{Cp}^*\text{IrCl}_2]_2$ (2.5 mol %), and Cs_2CO_3 (0.275 mmol). Isolated yields are given.

were recorded for the reaction with 7-methylindole (3c). The 4-MeO-, 5-Cl-, 6-OMe-, and 6-F-tryptamine derivatives (Table 2) were also obtained in decent yields, although the yields were lower than those of the 5-OMe analogue. Pleasingly, the presence of a substituent at C-2 did not impair the reaction, despite the potential steric crowding around the reaction site. Thus, the 2-Me-, 2-Ph-, and 2-Bn-indoles reacted efficiently with *N*-acetyethanolamine to give the corresponding trypt-

amines in 45–51% yields (Table 2). We also examined the efficacy of unsubstituted 7-azaindole 1k in undergoing C3-alkylation under the above reaction conditions. Treatment of 1k with *N*-acetyethanolamine (2a) furnished, selectively, the desired 7-azatryptamine (3k), although only in poor yield. In sharp contrast, *N*-methylindole (1l) proved to be inert, suggesting the involvement of the indole N–H in a key interaction with the base during the rate-determining step. It is noteworthy that the present method is a step-efficient and atom-economical route to the pineal hormone melatonin (3b), which has known sleep-inducing, antioxidant, and antiapoptotic properties,¹⁷ as well as to the reference MT₂ melatonin receptor ligand luzindole (3j), which is employed in pharmacological tests to evaluate and discriminate the roles of melatonin receptor subtypes.¹⁸

However, nearly complete recovery of the starting material was observed when a C3-substituted indole, such as 3-methyl- and 3-benzylindoles, were allowed to react with *N*-acetyethanolamine (2a) under the reaction conditions reported above. Neither indole annulations with dearomatization of the indole nucleus to pyrroloindolines products nor C3- to C2-alkyl migration and rearomatization to afford 2-substituted tryptamines were detected, in spite of recent reports.¹⁹

As mentioned previously, a major concern regarding *N*-protected ethanolamine reactions is the removal of the protecting group following successful functionalization/alkylation. To demonstrate the advantages of utilizing the *N*-acetyl protecting group, we sought to deprotect melatonin (3b) and *N*-acetyl-2-methyltryptamine (3h). To our delight, by treating 3b,h with a combination of ammonium bromide and ethylenediamine under microwave irradiation,²⁰ we were able to isolate the free 5-methoxytryptamine (7b) and 2-methyltryptamine (7h)²¹ in 89% and 78% yields, respectively, avoiding the use of strong acids or bases (Scheme 2).

Scheme 2. Removal of the *N*-Acetyl Protecting Group

CONCLUSION

In summary, the direct synthesis of diversely functionalized *N*-acetyltryptamines, including melatonin and luzindole, via the modern “borrowing hydrogen” strategy is presented. The new iridium-catalyzed C3-indole dehydration/alkylation protocol utilizes *N*-acetyethanolamine as a simple aminoethylene alkylating agent and source of hydrogen, avoiding the use of an external reducing agent. The experimental procedure for this metal-catalyzed direct alkylation of different indoles is simple and removal of side products is not a problem. This highly atom economical and environmentally benign process requires only inexpensive reagents, tolerates a range of functionalities, and may have applications in natural product synthesis and medicinal chemistry. The identification of more efficient catalytic systems to access a wider range of nitrogen-containing alcohols beyond ethanolamine as well as milder reaction conditions is the focus of current efforts in our laboratories.

EXPERIMENTAL SECTION

General Methods. All reactions were performed in a glass vial, under a nitrogen atmosphere. Column chromatographic purifications were performed under flash conditions using 230–400 mesh silica gel. Analytical thin-layer chromatography (TLC) was carried out on silica gel plates (silica gel 60 F₂₅₄), which were visualized by exposure to ultraviolet light and an aqueous solution of cerium ammonium molybdate (CAM) or *p*-anisaldehyde. ¹H NMR and ¹³C NMR spectra are provided in the Supporting Information. ¹H NMR and ¹³C NMR were recorded on a 200/50 or 400/100 spectrometer, using CDCl₃ as solvent. Chemical shifts (δ scale) are reported in parts per million (ppm) relative to the central peak of the solvent. Coupling constants (*J* values) are given in hertz (Hz). Molecular ions (*M* + 1) are given for ESI-MS analysis. Optical absorbances are reported in cm⁻¹ for the IR analyses. Melting points were determined on a capillary melting point apparatus and are uncorrected. Microwave-assisted reactions were carried out in a CEM Discover SP microwave reactor. Elemental analyses are within ± 0.4 of the theoretical values (C, H, N). 2-Benzyl-1H-indole,²² 2,2,2-trifluoro-*N*-(2-hydroxyethyl)acetamide,²³ benzyl 2-hydroxyethylcarbamate,²⁴ 2-(2-hydroxyethyl)isoindoline-1,3-dione,²⁵ and *N*-(2-hydroxyethyl)-4-methylbenzenesulfonamide²⁶ were synthesized according to the literature procedures. Other chemicals were purchased from commercial suppliers and were used without further purification.

General Procedure for the Synthesis of N-Protected Tryptamines. A mixture of the suitable indole **1a–h** (0.25 mmol), Cs₂CO₃ (90 mg, 0.275 mmol), [Cp*IrCl₂]₂ (5 mg, 0.00625 mmol), and the appropriate *N*-protected ethanolamine **2a–c** (0.75 mmol) was stirred under an N₂ atmosphere at 150 °C for 48 h in a sealed vial. After it was cooled to room temperature, the reaction mixture was dissolved in 1 mL of EtOAc/MeOH 9/1 and the solution filtered through a silica gel pad. The filtrate was concentrated in vacuo, and the residue was purified by flash column chromatography on silica gel.

***N*-(2-(1H-Indol-3-yl)ethyl)acetamide (3a).** This compound was prepared according to the general procedure from 1H-indole and *N*-(2-hydroxyethyl)acetamide. Flash chromatography (EtOAc) gave **3a** as a gray solid (30 mg, 0.15 mmol). Yield: 60%. Mp: 74–76 °C (CH₂Cl₂/petroleum ether). MS (ESI): 203 [M + H]⁺. ¹H NMR (200 MHz, CDCl₃): δ 1.92 (s, 3H), 2.98 (t, 2H, *J* = 6.6 Hz), 3.60 (dt, 2H, *J*₁ \approx *J*₂ = 6.6 Hz), 5.71 (br s, 1H), 7.05–7.27 (m, 3H), 7.39 (d, 1H, *J* = 8 Hz), 7.61 (d, 1H, *J* = 7.6 Hz), 8.51 (br s, 1H). The chemical and physical data are in accord with those in the literature.²⁷

***N*-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide (3b).** This compound was prepared according to the general procedure from 5-methoxy-1H-indole and *N*-(2-hydroxyethyl)acetamide. Flash chromatography (EtOAc) gave **3b** as a white solid (45 mg, 0.19 mmol). Yield: 78%. Mp: 114–116 °C (EtOAc). MS (ESI): 233 [M + H]⁺. ¹H NMR (200 MHz, CDCl₃): δ 1.94 (s, 3H), 2.94 (t, 2H, *J* = 6.6 Hz), 3.59 (dt, 2H, *J*₁ \approx *J*₂ = 6.6 Hz), 3.86 (s, 3H), 5.74 (br s, 1H), 6.87 (dd, 1H, *J* = 2.4 and *J* = 8.8 Hz), 7.00–7.05 (m, 2H), 7.27 (d, 1H, *J* = 8.8 Hz), 8.33 (br s, 1H). The chemical and physical data are in accord with those in the literature.²⁸

***N*-(2-(7-Methyl-1H-indol-3-yl)ethyl)acetamide (3c).** This compound was prepared according to the general procedure from 7-methyl-1H-indole and *N*-(2-hydroxyethyl)acetamide. Flash chromatography (EtOAc) gave **3c** as a brown oil (23 mg, 0.11 mmol). Yield: 43%. *R*_f = 0.28 (EtOAc). MS (ESI): 217 [M + H]⁺. ¹H NMR (200 MHz, CDCl₃): δ 1.93 (s, 3H), 2.51 (s, 3H), 2.98 (t, 2H, *J* = 6.5 Hz), 3.61 (dt, 2H, *J*₁ \approx *J*₂ = 6.5 Hz), 5.64 (br s, 1H), 7.01–7.12 (m, 3H), 7.45–7.48 (m, 1H), 8.28 (br s, 1H). ¹³C NMR (50 MHz, CDCl₃): δ 16.7, 23.4, 25.4, 39.9, 113.4, 116.4, 119.7, 120.6, 121.9, 122.7, 126.9, 136.0, 170.2. FTIR (film, cm⁻¹): 3399, 3285, 1646. Anal. Calcd for C₁₃H₁₆N₂O (216.13): C, 72.19; H, 7.46; N, 12.95. Found: C, 72.28; H, 7.39; N, 12.90.

***N*-(2-(4-Methoxy-1H-indol-3-yl)ethyl)acetamide (3d).** This compound was prepared according to the general procedure from 4-methoxy-1H-indole and *N*-(2-hydroxyethyl)acetamide. Flash chromatography (cyclohexane/EtOAc 1/1 to EtOAc) gave **3d** as a brown oil (25 mg, 0.11 mmol). Yield: 42%. MS (ESI): 233 [M + H]⁺. ¹H NMR

(200 MHz, CDCl₃): δ 1.89 (s, 3H), 3.08 (t, 2H, *J* = 6.2 Hz), 3.58 (dt, 2H, *J*₁ \approx *J*₂ = 6.2 Hz), 3.96 (s, 3H), 6.05 (br s, 1H), 6.52 (d, 1H, *J* = 7.6 Hz), 6.88–7.27 (m, 3H), 8.35 (br s, 1H). The chemical and physical data are in accord with those in the literature.²⁹

***N*-(2-(5-Chloro-1H-indol-3-yl)ethyl)acetamide (3e).** This compound was prepared according to the general procedure from 5-chloro-1H-indole and *N*-(2-hydroxyethyl)acetamide. Flash chromatography (EtOAc/cyclohexane 9/1) gave **3e** as a gray solid (29 mg, 0.12 mmol). Yield: 49%. Mp: 149–151 °C (EtOAc/petroleum ether). MS (ESI): 237 [M + H]⁺. ¹H NMR (200 MHz, CDCl₃): δ 1.95 (s, 3H), 2.91 (t, 2H, *J* = 6.8 Hz), 3.55 (dt, 2H, *J*₁ \approx *J*₂ = 6.8 Hz), 5.78 (br s, 1H), 7.03–7.04 (m, 1H), 7.11–7.31 (m, 2H), 7.53–7.54 (m, 1H), 8.72 (br s, 1H). The chemical and physical data are in accord with those in the literature.³⁰

***N*-(2-(6-Methoxy-1H-indol-3-yl)ethyl)acetamide (3f).** This compound was prepared according to the general procedure from 6-methoxy-1H-indole and *N*-(2-hydroxyethyl)acetamide. Flash chromatography (EtOAc) gave **3f** (35 mg, 0.15 mmol). Yield: 61%. Mp: 136–137 °C. MS (ESI): 233 [M + H]⁺. ¹H NMR (400 MHz, CDCl₃): δ 1.93 (s, 3H), 2.94 (t, 2H, *J* = 6.6 Hz), 3.59 (dt, 2H, *J*₁ \approx *J*₂ = 6.6 Hz), 3.86 (s, 3H), 5.57 (br s, 1H), 6.81 (dd, 1H, *J* = 2.2 e *J* = 8.6 Hz), 6.88 (d, 1H, *J* = 2.2), 6.93 (d, 1H, *J* = 2.0), 7.47 (d, 1H, *J* = 8.6 Hz), 8.04 (br s, 1H). The chemical and physical data are in accord with those in the literature.³⁰

***N*-(2-(6-Fluoro-1H-indol-3-yl)ethyl)acetamide (3g).** This compound was prepared according to the general procedure from 6-fluoro-1H-indole and *N*-(2-hydroxyethyl)acetamide. Flash chromatography (EtOAc) gave **3g** as a brown oil (20 mg, 0.09 mmol). Yield: 37%. MS (ESI): 221 [M + H]⁺. ¹H NMR (200 MHz, CDCl₃): δ 1.95 (s, 3H), 2.95 (t, 2H, *J* = 6.7 Hz), 3.59 (dt, 2H, *J*₁ \approx *J*₂ = 6.7 Hz), 5.67 (br s, 1H), 6.84–6.94 (m, 1H), 7.01–7.09 (m, 2H), 7.46–7.53 (m, 1H), 8.43 (br s, 1H). The chemical and physical data are in accord with those in the literature.³¹

***N*-(2-(2-Methyl-1H-indol-3-yl)ethyl)acetamide (3h).** This compound was prepared according to the general procedure from 2-methyl-1H-indole and *N*-(2-hydroxyethyl)acetamide. Flash chromatography (EtOAc) gave **3h** as a yellow solid (24 mg, 0.11 mmol). Yield: 45%. Mp: 83–85 °C (CH₂Cl₂/petroleum ether). MS (ESI): 217 [M + H]⁺. ¹H NMR (200 MHz, CDCl₃): δ 1.90 (s, 3H), 2.39 (s, 3H), 2.92 (t, 2H, *J* = 6.5 Hz), 3.50 (dt, 2H, *J*₁ \approx *J*₂ = 6.5 Hz), 5.59 (br s, 1H), 7.08–7.15 (m, 2H), 7.27–7.32 (m, 1H), 7.48–7.52 (m, 1H), 8.08 (br s, 1H). The chemical and physical data are in accord with those in the literature.^{8a}

***N*-(2-(2-Phenyl-1H-indol-3-yl)ethyl)acetamide (3i).** This compound was prepared according to the general procedure from 2-phenyl-1H-indole and *N*-(2-hydroxyethyl)acetamide. Flash chromatography (EtOAc/cyclohexane 6/4 to 9/1) gave **3i** as a yellow solid (32 mg, 0.12 mmol). Yield: 46%. Mp: 114–116 °C (CH₂Cl₂/petroleum ether). MS (ESI): 279 [M + H]⁺. ¹H NMR (200 MHz, CDCl₃): δ 1.77 (s, 3H), 3.14 (t, 2H, *J* = 6.6 Hz), 3.56 (dt, 2H, *J*₁ \approx *J*₂ = 6.6 Hz), 5.51 (br s, 1H), 7.13–7.29 (m, 2H), 7.35–7.68 (m, 7H), 8.31 (br s, 1H). The chemical and physical data are in accord with those in the literature.^{8a}

***N*-(2-(2-Benzyl-1H-indol-3-yl)ethyl)acetamide (3j).** This compound was prepared according to the general procedure from 2-benzyl-1H-indole and *N*-(2-hydroxyethyl)acetamide. Flash chromatography (EtOAc/cyclohexane 1/1 to EtOAc) gave **3j** as a light oil (37 mg, 0.13 mmol). Yield: 51%. MS (ESI): 293 [M + H]⁺. ¹H NMR (200 MHz, CDCl₃): δ 1.76 (s, 3H), 2.98 (t, 2H, *J* = 6.5 Hz), 3.51 (dt, 2H, *J*₁ \approx *J*₂ = 6.5 Hz), 4.10 (s, 2H), 5.51 (br s, 1H), 7.09–7.31 (m, 8H), 7.51–7.60 (m, 1H), 7.99 (br s, 1H). The chemical and physical data are in accord with those in the literature.^{8a}

***N*-(2-(1H-Pyrrolo[2,3-*b*]pyridin-3-yl)ethyl)acetamide (3k).** This compound was prepared according to the general procedure from 1H-pyrrolo[2,3-*b*]pyridine and *N*-(2-hydroxyethyl)acetamide. Flash chromatography (EtOAc/MeOH 95/5 to 9/1) gave **3k** as a white solid (18 mg, 0.09 mmol). Yield: 36%. Mp: 175–177 °C (EtOAc). *R*_f = 0.23 (EtOAc/MeOH 95/5). MS (ESI): 204 [M + H]⁺. ¹H NMR (400 MHz, CDCl₃): δ 1.95 (s, 3H), 2.98 (t, 2H, *J* = 6.7 Hz), 3.60 (dt, 2H, *J*₁ \approx *J*₂ = 6.7 Hz), 5.58 (br s, 1H), 7.11 (dd, 1H, *J* = 4.7 Hz and *J* =

7.8 Hz), 7.19 (s, 1H), 7.96 (d, 1H, $J = 7.8$ Hz), 8.33 (d, 1H, $J = 3.6$ Hz), 10.03 (br s, 1H). ^{13}C NMR (100 MHz, CDCl_3): δ 23.3, 25.5, 39.8, 111.6, 115.6, 120.0, 122.5, 127.3, 142.9, 148.7, 170.1. FTIR (film, cm^{-1}): 3285, 1630. Anal. Calcd for $\text{C}_{11}\text{H}_{13}\text{N}_3\text{O}$ (203.11): C, 65.01; H, 6.45; N, 20.68. Found: C, 65.09; H, 6.39; N, 20.71.

N-(2,2-Bis(1*H*-indol-3-yl)ethyl)acetamide (**4**). This compound was obtained and isolated as a reaction byproduct under the conditions reported in the general procedure employing 1*H*-indole and *N*-(2-hydroxyethyl)acetamide. Yield: 9% (7 mg, 0.02 mmol). MS (ESI): 318 $[\text{M} + \text{H}]^+$. ^1H NMR (200 MHz, CDCl_3): δ 1.90 (s, 3H), 4.07 (m, 2H), 4.75 (t, 1H, $J = 7.1$ Hz), 5.60 (br s, 1H), 7.04–7.11 (m, 4H), 7.16–7.24 (m, 2H), 7.37–7.41 (m, 2H), 7.60–7.64 (m, 2H), 8.07 (br s, 2H). The chemical and physical data are in accord with those in the literature.³²

2-(1*H*-Indol-3-yl)ethanol (**5**). This compound was obtained and isolated as a reaction byproduct under the conditions reported in the general procedure employing 1*H*-indole and *N*-(2-hydroxyethyl)acetamide. Yield: 6% (2 mg, 0.015 mmol). MS (ESI): 162 $[\text{M} + \text{H}]^+$. ^1H NMR (400 MHz, CDCl_3): δ 3.03 (dt, 2H, $J = 0.5$ Hz and $J = 6.3$ Hz), 3.91 (t, 2H, $J = 6.3$ Hz), 7.07–7.26 (m, 3H), 7.38 (d, 1H, $J = 8.0$ Hz), 7.62 (d, 1H, $J = 8.0$ Hz), 8.07 (br s, 1H). The chemical and physical data are in accord with those in the literature.³³

N-Benzyl-2-(1*H*-indol-3-yl)ethanamine (**6c**). This compound was prepared according to the general procedure from 1*H*-indole and 2-(benzylamino)ethanol. Flash column chromatography (EtOAc to EtOAc/MeOH 9/1) gave the compound as a brown oil (25 mg, 0.1 mmol). Yield: 40%. MS (ESI): 251 $[\text{M} + \text{H}]^+$. ^1H NMR (200 MHz, CDCl_3): δ 3.00 (app. s, 4H), 3.81 (s, 2H), 6.99–7.35 (m, 10H), 7.60 (d, 1H, $J = 7.5$ Hz), 8.15 (br s, 1H). The chemical and physical data are in accord with those in the literature.³⁴

2-(1*H*-Indol-3-yl)-*N,N*-dimethylethanamine (**6d**). This compound was prepared according to the general procedure from 1*H*-indole and 2-(dimethylamino)ethanol. Flash chromatography ($\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{TEA}$ 93/6/1) gave **6d** as a brown oil (20 mg, 0.11 mmol). Yield: 42%. MS (ESI): 189 $[\text{M} + \text{H}]^+$. ^1H NMR (400 MHz, CDCl_3): δ 2.36 (s, 6H), 2.64–2.68 (m, 2H), 2.94–2.98 (m, 2H), 7.03 (s, 1H), 7.11–7.15 (m, 1H), 7.18–7.22 (m, 1H), 7.36 (d, $J = 8.0$ Hz, 1H), 7.63 (d, $J = 8.0$ Hz, 1H), 8.11 (br s, 1H). The chemical and physical data are in accord with those in the literature.³⁵

General Procedure for the N-Deacetylation. Ammonium bromide (49 mg, 0.5 mmol), ethylenediamine (0.135 mL, 2 mmol), and *N*-acetyltryptamine derivative (0.5 mmol) were mixed in a suitable vial fitted with a magnetic stirrer. The mixture was then heated to 100 °C in a microwave apparatus (250 W) for 7 h. After it was cooled to room temperature, the crude reaction mixture was diluted with CH_2Cl_2 and the desired tryptamine was extracted with an aqueous solution of 1 M HCl. The aqueous layer was then made basic by addition of aqueous NaOH (1 M) and then extracted with CH_2Cl_2 . The combined organic phases were washed with brine, dried over Na_2SO_4 , and concentrated by distillation at reduced pressure, giving a crude residue which was purified by filtration on a flash chromatographic column of silica gel ($\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{TEA}$ 90/9/1).

2-(5-Methoxy-1*H*-indol-3-yl)ethanamine (**7b**). This compound was obtained as a colorless oil (85 mg, 0.45 mmol). Yield: 89%. MS (ESI): 191 $[\text{M} + \text{H}]^+$. ^1H NMR (200 MHz, CDCl_3): δ 1.98 (br s, 2H), 2.85–2.91 (m, 2H), 2.99–3.06 (m, 2H), 3.87 (s, 3H), 6.83–6.89 (m, 1H), 7.0 (s, 1H), 7.04–7.05 (m, 1H), 7.22–7.27 (m, 1H), 8.46 (br s, 1H). The chemical and physical data are in accord with those in the literature.³⁶

2-(2-Methyl-1*H*-indol-3-yl)ethanamine (**7h**). This compound was obtained as a pale yellow amorphous solid (68 mg, 0.39 mmol). Yield: 78%. MS (ESI): 175 $[\text{M} + \text{H}]^+$. ^1H NMR (400 MHz, CDCl_3): δ 1.76 (br s, 2H), 2.38 (s, 3H), 2.83–2.87 (m, 2H), 2.95–2.99 (m, 2H), 7.05–7.13 (m, 2H), 7.26 (d, $J = 7.5$ Hz, 1H), 7.50 (d, $J = 7.5$ Hz, 1H), 8.00 (br s, 1H). The chemical and physical data are in accord with those in the literature.^{8a}

■ ASSOCIATED CONTENT

📄 Supporting Information

Figures giving ^1H and ^{13}C NMR spectra for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail for G.P.: giovanni.piersanti@uniurb.it.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This work was partially supported by the Italian MIUR (Ministero dell'Istruzione, dell'Università della Ricerca) and University of Urbino "Carlo Bo".

■ REFERENCES

- (1) (a) Mizoguchi, H.; Oikawa, H.; Oguri, H. *Nat. Chem.* **2014**, *6*, 57. (b) Rungphan, W.; O'Connor, S. E. *Org. Lett.* **2013**, *15*, 2850. (c) Dewick, P. M.; *Medicinal Natural Products: A Biosynthetic Approach*, 3rd ed.; Wiley: Chichester, U.K., 2009.
- (2) (a) Inman, M.; Moody, C. J. *Chem. Sci.* **2013**, *4*, 29. (b) Zhang, D.; Song, H.; Qin, Y. *Acc. Chem. Res.* **2011**, *44*, 447. (c) Kochanowska-Karamyan, A. J.; Hamann, M. T. *Chem. Rev.* **2010**, *110*, 4489. (d) Cao, R.; Peng, W.; Wang, Z.; Xu, A. *Curr. Med. Chem.* **2007**, *14*, 479. (e) Czarnocki, Z.; Siwicka, A.; Szawka, J. *Curr. Org. Synth.* **2005**, *2*, 301. (f) Barceloux, D. G. *Tryptamine Designer Drugs*. In *Medical Toxicology of Drug Abuse*; Wiley: Hoboken, NJ, 2012; p 193.
- (3) (a) Bartoli, G.; Bencivenni, G.; Dalpozzo, R. *Chem. Soc. Rev.* **2010**, *39*, 4449. (b) Zeng, M.; You, S.-L. *Synlett* **2010**, *9*, 1289. (c) Bandini, M.; Eichholzer, A. *Angew. Chem., Int. Ed.* **2009**, *48*, 9608. (d) Bandini, M.; Melloni, A.; Tommasi, S.; Umani-Ronchi, A. *Synlett* **2005**, *8*, 1199.
- (4) (a) Harrington, P. E.; Kerr, M. A. *Synlett* **1996**, *11*, 1047. (b) Bandini, M.; Melchiorre, P.; Melloni, A.; Umani-Ronchi, A. *Synthesis* **2002**, *8*, 1110. (c) Bandini, M.; Garelli, A.; Rovinetti, M.; Tommasi, S.; Umani-Ronchi, A. *Chirality* **2005**, *17*, 522. (d) Yokohama, N.; Arai, T. *Chem. Commun.* **2009**, *22*, 3285. (e) Ara, T.; Wasai, M.; Yokohama, N. *J. Org. Chem.* **2011**, *76*, 2909. (f) Jia, Y.; Yang, W.; Du, D. M. *Org. Biomol. Chem.* **2012**, *10*, 4739. (g) Zhang, W.; Hazell, R. G.; Jorgensen, K. A. *Org. Biomol. Chem.* **2005**, *3*, 2566. (h) Dessole, G.; Herrera, R. P.; Ricci, A. *Synlett* **2004**, *13*, 2374. (i) Wu, P.; Wan, Y.; Cai, J. *Synlett* **2008**, *8*, 1193.
- (5) For selected examples, see: (a) Wang, S.; Chai, Z.; Zhou, S.; Wang, S.; Zhu, X.; Wei, Y. *Org. Lett.* **2013**, *15*, 2628. (b) Ghorai, M. K.; Tiwari, D. P.; Jain, N. *J. Org. Chem.* **2013**, *78*, 7121. (c) Kaiser, H. M.; Lo, W.; Riah, A. M.; Spannenberg, A.; Beller, M.; Tse, M. K. *Org. Lett.* **2006**, *8*, 5761. (d) Ezquerro, J.; Pedregal, C.; Lamas, C. *Tetrahedron Lett.* **1996**, *37*, 683. For selected examples of ring-opening reactions of enantioenriched aziridines with indoles, see: (e) Hudlicky, T.; Rinner, U.; Finn, K. J.; Ghiviriga, I. *J. Org. Chem.* **2005**, *70*, 3490. (f) Rinner, U.; Hudlicky, T.; Gordon, H.; Pettit, G. R. *Angew. Chem., Int. Ed.* **2004**, *43*, 5342; *Angew. Chem.* **2004**, *116*, 5456. (g) Tirota, I.; Fifer, N. L.; Eakins, J.; Hutton, C. A. *Tetrahedron Lett.* **2013**, *54*, 618. (h) Li, Y.; Hayman, E.; Plesescu, M.; Prakash, S. R. *Tetrahedron Lett.* **2008**, *49*, 1480. (i) Menguy, L.; Lo, C.; Marrot, J.; Couty, F. *Tetrahedron* **2014**, *70*, 4512. For an elegant highly regioselective and enantiospecific ring-opening reaction of enantioenriched aziridines with indoles, see: (j) Cockrell, J.; Wilhelmsen, C.; Rubin, H.; Martin, A.; Morgan, J. B. *Angew. Chem., Int. Ed.* **2012**, *51*, 9842; *Angew. Chem.* **2012**, *124*, 9980.
- (6) (a) Woo, Y.; Lai, D. Y.; Argus, M. F.; Arcos, J. C. *Toxicol. Lett.* **1995**, *79*, 219. (b) Talalay, P.; De Long, M. J.; Prochaska, H. J. *Proc. Natl. Acad. Sci. U.S.A.* **1988**, *85*, 8261.

- (7) Lancianesi, S.; Palmieri, A.; Petrini, M. *Chem. Rev.* **2014**, *114*, 7108.
- (8) (a) Righi, M.; Topi, F.; Bartolucci, S.; Bedini, A.; Piersanti, G.; Spadoni, G. *J. Org. Chem.* **2012**, *77*, 6351. For other uses of α -amidoacetals, see: (b) Righi, M.; Bedini, A.; Piersanti, G.; Romagnoli, F.; Spadoni, G. *J. Org. Chem.* **2011**, *76*, 704.
- (9) (a) Grigg, R.; Mitchell, T. R. B.; Sutthivaiyakit, S.; Tongpenyai, N. *Tetrahedron Lett.* **1981**, *22*, 4107. (b) Tsuji, T.; Huh, K.-T.; Ohsugi, Y.; Watanabe, Y. *J. Org. Chem.* **1985**, *50*, 1365.
- (10) For selected reviews, see: (a) Gunanathan, C.; Milstein, D. *Science* **2013**, *341*, 249. (b) Bähn, S.; Imm, S.; Neubert, L.; Zhang, M.; Neumann, H.; Beller, M. *ChemCatChem* **2011**, *3*, 1853. (c) Watson, A. J. A.; Williams, J. M. J. *Science* **2010**, *329*, 635. (d) Dobereiner, G. E.; Crabtree, R. H. *Chem. Rev.* **2010**, *110*, 681. (e) Guillena, G.; Ramón, D. J.; Yus, M. *Chem. Rev.* **2010**, *110*, 1611.
- (11) For recent reviews with regard to C–C couplings, see: (a) Obora, Y. *ACS Catal.* **2014**, *4*, 3972. (b) Pan, S.; Shibata, T. *ACS Catal.* **2013**, *3*, 704.
- (12) For an example of a tandem oxidative cyclization/alkylation of 2-aminophenyl ethyl alcohol and *N,N*-dimethylethanolamine, for the synthesis of *N,N*-dimethyltryptamine, see: (a) Whitney, S.; Grigg, R.; Derrick, A.; Keep, A. *Org. Lett.* **2007**, *9*, 3299. For other coupling reactions of indoles with simple benzylic alcohols or aliphatic alcohols, see: (b) Bahn, S.; Imm, S.; Mevius, K.; Neubert, L.; Tillack, A.; Williams, J. M. J.; Beller, M. *Chem. Eur. J.* **2010**, *16*, 3590. (c) Putra, A. E.; Takigawa, K.; Tanaka, H.; Ito, Y.; Oe, Y.; Ohta, T. *Eur. J. Org. Chem.* **2013**, *28*, 6344. (d) Hakim Siddiki, S. M. A.; Kon, K.; Shimizu, K. *Chem. Eur. J.* **2013**, *43*, 14416. (e) Cano, R.; Yus, M.; Ramón, D. J. *Tetrahedron Lett.* **2013**, *54*, 3394.
- (13) For other uses of the catalyst $[\text{Cp}^*\text{IrCl}_2]_2$ for C–C couplings with borrowing hydrogen methodologies, see: (a) Löfberg, C.; Grigg, R.; Whittaker, M. A.; Keep, A.; Derrick, A. *J. Org. Chem.* **2006**, *71*, 8023. (b) Anxionnat, B.; Pardo, D. G.; Ricci, G.; Cossy, J. *Org. Lett.* **2011**, *13*, 4084. (c) Anxionnat, B.; Domingo, G. P.; Ricci, G.; Cossy, J. *Eur. J. Org. Chem.* **2012**, *24*, 4453. (d) Anxionnat, B.; Pardo, D. G.; Ricci, G.; Rossen, K.; Cossy, J. *Org. Lett.* **2013**, *15*, 3876.
- (14) (a) Mari, M.; Tassoni, A.; Lucarini, S.; Fanelli, M.; Piersanti, G.; Spadoni, G. *Eur. J. Org. Chem.* **2014**, *18*, 3822. (b) For a good review, see: Palmieri, A.; Petrini, M.; Shaikh, R. R. *Org. Biomol. Chem.* **2010**, *8*, 1259.
- (15) Hamid, M. H. S. A.; Allen, C. L.; Lamb, G. W.; Maxwell, A. C.; Maytum, H. C.; Watson, A. J. A.; Williams, J. M. J. *J. Am. Chem. Soc.* **2009**, *131*, 1766.
- (16) For alkylations of indole using amines, see: (a) Imm, S.; Bhan, S.; Tillack, A.; Mevius, K.; Neubert, L.; Beller, M. *Chem. Eur. J.* **2010**, *16*, 2705. (b) Lerch, S.; Unkel, L.-N.; Brasholz, M. *Angew. Chem., Int. Ed.* **2014**, *53*, 6558.
- (17) (a) Tan, D.-X.; Manchester, L. C.; Terron, M. P.; Flores, L. J.; Reiter, R. J. *J. Pineal Res.* **2007**, *42*, 28. (b) Spadoni, G.; Bedini, A.; Rivara, S.; Mor, M. *CNS Neurosci. Ther.* **2011**, *17*, 733.
- (18) Dubocovich, M. L.; Yun, K.; Al-Ghoul, W. M.; Benloucif, S.; Masana, M. I. *FASEB J.* **1998**, *12*, 1211.
- (19) (a) Mari, M.; Lucarini, S.; Bartoccini, F.; Piersanti, G.; Spadoni, G. *Beilstein J. Org. Chem.* **2014**, *10*, 1991. (b) Wang, H.; Reisman, S. E. *Angew. Chem., Int. Ed.* **2014**, *53*, 6206. (c) Wang, L.; Yang, D.; Han, F.; D. Li, D.; D. Zhao, D.; R. Wang, R. *Org. Lett.* **2015**, *17*, 176. (d) Kandukuri, S. R.; Bahamonde, A.; Chatterjee, I.; Jurberg, I. D.; Escudero-Adán, E. C.; Melchiorre, P. *Angew. Chem., Int. Ed.* **2015**, *54*, 1485.
- (20) Shimizu, Y.; Morimoto, H.; Zhang, M.; Ohshima, T. *Angew. Chem., Int. Ed.* **2012**, *51*, 8564.
- (21) For the importance of 2-methyltryptamine in medicinal chemistry, see: (a) Slade, J.; Parker, D.; Girgis, M.; Wu, R.; Joseph, S.; Repič, O. *Org. Process Res. Dev.* **2007**, *11*, 721. (b) René, O.; Fauber, B. P. *Tetrahedron Lett.* **2014**, *55*, 830.
- (22) Wiedenau, P.; Blechert, S. *Synth. Commun.* **1997**, *27*, 2033.
- (23) Khuizen, E. C.; Kiessling, L. L. *Org. Lett.* **2009**, *11*, 193.
- (24) De Cola, C.; Manicardi, A.; Corradini, R.; Izzo, I.; De Riccardis, F. *Tetrahedron* **2012**, *68*, 499.
- (25) Kolomiets, E.; Buhler, E.; Candau, S. J.; Lehn, J.-M. *Macromolecules* **2006**, *39*, 1173.
- (26) Balaji, P. V.; Chandrasekaran, S. *Chem. Commun.* **2014**, *50*, 70–72.
- (27) Schuck, D. C.; Jordao, A. K.; Nakabashi, M.; Cunha, A. C.; Ferreira, V. F.; Garcia, C. R. S. *Eur. J. Med. Chem.* **2014**, *78*, 375.
- (28) Hwang, K. J.; Lee, T. S. *Synth. Commun.* **1999**, *29*, 2099.
- (29) Yamada, F.; Saida, Y.; Somei, M. *Heterocycles* **1986**, *24*, 2619.
- (30) Mor, M.; Rivara, S.; Silva, C.; Bordi, F.; Palazzi, P. V.; Spadoni, G.; Diamantini, G.; Tarzia, G.; Frascini, F.; Lucini, V.; Nonno, R.; Stankov, B. M. *J. Med. Chem.* **1998**, *41*, 3831.
- (31) Yang, S.-W.; Cordell, G. A. *J. Nat. Prod.* **1997**, *60*, 44.
- (32) Chakrabarty, M.; Ghosh, N.; Basak, R.; Harigaya, Y. *Synth. Commun.* **2004**, *34*, 421–434.
- (33) Du, Y.; Huang, H.-Y.; Liu, H.; Ruan, Y.-P.; Huang, P.-Q. *Synlett* **2011**, *4*, 565.
- (34) Cho, C. S.; Kim, B. T.; Kim, T.-J.; Shim, S. C. *J. Org. Chem.* **2001**, *66*, 9020.
- (35) Shi-Jin, Q.; Wang, G.-F.; Duan, W.-H.; Yao, S.-Y.; Zuo, J.-P.; Tan, C.-H.; Zhu, D.-Y. *Bioorg. Med. Chem.* **2011**, *19*, 3120.
- (36) Revial, G.; Jabin, I.; Lim, S.; Pfau, M. *J. Org. Chem.* **2002**, *67*, 2252.